Evidence map›Paper›PMID 34152569›Full record

ArticleAnnals of nuclear medicine2021

The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer.

Domenico Albano, Francesco Dondi, Valentina Zilioli, Maria Beatrice Panarotto, Alessandro Galani, Carlo Cappelli, Francesco Bertagna, Raffaele Giubbini, Claudio Casella

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Domenico AlbanoNuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, Brescia, Italy. doalba87@libero.it.ORCID http://orcid.org/0000-0003-0810-6494
Francesco DondiNuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, Brescia, Italy.
Valentina ZilioliNuclear Medicine Department, ASST Spedali Civili Brescia, Brescia, Italy.
Maria Beatrice PanarottoNuclear Medicine Department, ASST Spedali Civili Brescia, Brescia, Italy.
Alessandro GalaniDepartment of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, Brescia, Italy.
Carlo CappelliDepartment of Clinical and Experimental Sciences, SSd Medicina ad Indirizzo Endocrino-Metabolico, University of Brescia, Brescia, Italy.
Francesco BertagnaNuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, Brescia, Italy.
Raffaele GiubbiniNuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, Brescia, Italy.
Claudio CasellaDepartment of Molecular and Translation Medicine, Surgical Clinic, University of Brescia, Brescia, Italy.
University of Brescia · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe baseline treatment of differentiated thyroid cancer (DTC) consists of thyroidectomy followed by postoperative risk-adapted radioiodine therapy (RAIT) when indicated. The choice of most appropriate RAI activities to administer with the aim to reach an efficient remnant ablation and reduce the risk of recurrence is yet an open issue and the detection of basal factors that may predict treatment response seems fundamental. The aim of this study was to investigate the potential role of Hashimoto thyroiditis (HT) in predicting 1-year and 5-year treatment response after RAIT and prognosis.

methodsWe retrospectively included 314 consecutive patients (174 low-risk and 140 intermediate-risk) who received thyroidectomy plus RAIT. One-year and 5-year disease status was evaluated according to 2015 ATA categories response based upon biochemical and structural findings.

resultsHT was reported histopathologically in 120 patients (38%). DTC patients with concomitant HT received a higher number of RAITs and cumulative RAI activities. Initial RAIT reached an excellent response in 63% after one year and 84% after 5 years. The rate of excellent response one year and 5-year after first RAIT was significantly lower in HT groups, compared to not HT (p < 0.001). Instead, HT did not have a prognostic role considering PFS and OS; while stimulate thyroglobulin (sTg) at ablation was significantly related to survival.

conclusionsHT may affect the efficacy of RAIT in low to intermediate risk DTC, particularly reducing the successful rate of excellent response after RAIT. Instead, HT did not have a prognostic impact such as stimulated sTg.

Indexed as

Hashimoto DiseaseIodine RadioisotopesThyroid NeoplasmsAblation TechniquesAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesThyroidectomyTreatment OutcomeIodine RadioisotopesAblationDifferentiated thyroid cancerHashimoto thyroiditisRAI

Identifiers

PMID34152569
PMCPMC8408084
OpenAlexW3174208837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.